A. All Articles and Material should be submitted on-line via EES http://ees.elsevier.com/tr.
Please refer to the 'Tutorial for Authors' located on the EES site for guidance on the electronic submission process.
If you are
unable to submit online or have any general queries, please contact the Editorial Offices regarding alternatives.
Editor in Chief
for the Americas (USA, Canada, Mid - and South America):
Dr Charles Francis, Hematology/Oncology, University of Rochester Medical Center,
PO Box 610, Rochester NY 14642, USA; Fax: +1 585-473-4314.
Editor-in-Chief for the Rest of the world:
P.M.Sandset, Ulleval University
Hospital, Department of Hematology, Hematological Research Lab., N-00407 Oslo, Norway; Fax: +47 221 19040; Email: thrombosis-research@ioks.uio.no
Editor-in-Chief for Review Articles:
Dr Nigel Key, University of North Carolina, 932 Mary Ellen Jones Building, CB #7035, Chapel
Hill, NC 27599, USA; Email: nigel_key@med.unc.edu
Communication Categories: Several categories of manuscripts will be considered
for publication. (1) Original Articles are full length reports of original work. (2) Review Articles constitute a literature
review of a particular area and can be clinical or concentrate on a basic science topic. Review Articles are often commissioned but if
you would like to submit a proposal, please contact Dr Nigel Key at the above address. Proposals for a series of review articles under
one main heading will also be considered. (3) Short Communications address practical problems in the laboratory and in clinical
investigation - only exceptional or outstanding communications will be published. (4) Letters to the Editors-in-Chief. These
contributions should be concerned with matters of opinion and criticism on contributions published in the journal and other matters of
interest to researchers in our field. (5) Editorials provide comments on matters significant to the readers of Thrombosis Research.
(6) Reports of Scientific Meetings are published from time-to-time. Please contact the Editors-in-Chief regarding these. (7) Supplement issues may cover various topics in the field of thrombosis and hemostasis. They are approved by the Editors-in-Chief
and edited preferably by one of the Editors of Thrombosis Research. In addition to the above categories various News Items and Announcements
are printed.
Length of Communications: Authors are asked to limit their (a) Original Articles and Reports of Scientific Meetings
to 5-6,000 words, (b) Short Communications to 3,000 words, (c) Letters to the Editors-in-Chief to 1,500 words, and (d) News Items and
Announcements to 500 words. The length of review articles is flexible and should be discussed with Dr Nigel Key on a case-by-case basis.
Although these limits are not strictly enforced, a page charge of US$ 50 for each additional page exceeding these limits will be billed
by the publisher to the authors.
Authorship: All authors should have made substantial contributions to all of the following:
(1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article
or revising it critically for important intellectual content, (3) final approval of the version to be submitted.
Acknowledgements:
All contributors who do not meet the criteria for authorship as defined above should be listed in an acknowledgements section. Examples
of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair who
provided only general support. Authors should disclose whether they had any writing assistance and identify the entity that paid for
this assistance.
Conflict of interest: At the end of the text, under a subheading "Conflict of interest statement"
all authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence
(bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert
testimony, patent applications/registrations, and grants or other funding.
Role of the funding source: All sources of funding
should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the study
design, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript
for publication. If the study sponsors had no such involvement, the authors should so state.
Randomised controlled trials:
All randomised controlled trials submitted for publication in Thrombosis Research should include a completed Consolidated Standards
of Reporting Trials (CONSORT) flow chart. Please refer to the CONSORT statement website at http://www.consort-statement.org
for more information. Thrombosis Research has adopted the proposal from the International Committee of Medical Journal Editors
(ICMJE) which require, as a condition of consideration for publication of clinical trials, registration in a public trials registry.
Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end
of the abstract of the article. For this purpose, a clinical trial is defined as any research project that prospectively assigns human
subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health
outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g. phase I trials) would be exempt.
Further information can be found at www.icmje.org.
Ethics: Work on human beings that is submitted to Thrombosis
Research should comply with the principles laid down in the Declaration of Helsinki; Recommendations guiding physicians in biomedical
research involving human subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964, amended by the 29th World
Medical Assembly, Tokyo, Japan, October 1975, the 35th World Medical Assembly, Venice, Italy, October 1983, and the 41st World Medical
Assembly, Hong Kong, September 1989. The manuscript should contain a statement that the work has been approved by the appropriate ethical
committees related to the institution(s) in which it was performed and that subjects gave informed consent to the work. Studies involving
experiments with animals must state that their care was in accordance with institution guidelines. Patients' and volunteers' names, initials,
and hospital numbers should not be used.
II. FORMATTING INSTRUCTIONS
General Information: It is the responsibility
of the authors to write in standard, grammatical English. Spelling may be British or American, but must be consistent throughout the
text, tables and legends to tables and figures. A word count should be provided in the 'Enter Comments' section of EES and on the title
page of the manuscript file. Original articles should be organised as follows: (a) Title page; (b) Abstract, Keywords, and Abbreviations;
(c) Text with the following sections; Introduction, Materials and Methods, Results, Discussion, Acknowledgments; (d) References; (e)
Tables; (f) Table Legends and Figure Legends. The pages should be numbered consecutively; the Title page is page 1, the Abstract page
2, etc. throughout the manuscript (including References, Tables, and Legends to Tables and Figures). Brief Communications have
no abstract but a summary at the end of the discussion. (a) Title Page: Identify the category of the communication on top
of the page. Include a brief and descriptive Title of the article, the full Name(s) of the Author(s)(in the format First Name, Initials,
and Surname) and the Name and Location of the institution where the research was carried out. A word count of the text should include
Tables and Legends. Exclude the Abstract and Reference list. The name, postal and email addresses, telephone and fax numbers of the corresponding
author should be included at the bottom of the title page as well as, if necessary, additional addresses of other Authors. If the manuscript
was presented at a meeting, the name of the organization, the place and the date on which it was read must be indicated. (b)
Abstract Page: Abstracts are required for original articles only. The abstract is essential and the most read part of the paper.
It should be informative, not descriptive, and should avoid abbreviations except for units of measure. An abstract for a regular article
should not exceed 250 words and should end with the principal conclusions of the study. Structured abstracts are encouraged and should
use the following headings: Introduction, Materials and Methods, Results and Conclusions. Keywords and Abbreviations should
follow the abstract and be on the same page (or on a separate page if no abstract). List up to 6 key words for subject indexing, preferably
to be taken from Index Medicus. List all abbreviations used. (c) Text of Articles: The text should be arranged as follows: Introduction, without heading, should state the purpose of the investigation and give a short review of pertinent literature. Materials and methods should be described in detail with appropriate information about patients or experimental animals.
Authors should stipulate that informed consent was obtained when applicable to research on humans, with the comment that the
study was approved by the institutional Ethics Committee on human research. Manuscripts reporting animal experiments must include
the statement that all animals received care in compliance with the American, European, or any other Convention on Animal Care, with
the comment that the study was approved by the institutional Ethics Committee. Generic names of drugs and equipment should be used throughout
the manuscript with brand names (proprietary name) and the name and location (city, state, country) of the manufacturer in parentheses
when first mentioned in the text. Results should be reported concisely. Results presented either in tables or figures should
be commented on in the text. Discussion is an interpretation of the results and their significance with reference to pertinent
work by other authors. It should be clear and concise. The importance of the study and its limitations should be discussed. Acknowledgments
of financial or personal assistance should be placed at the end of the text. (d) References: Consecutive numbers in square
brackets should be used to indicate references in the text, e.g., [1,2], as part of the text and not raised above it.
The full reference
should be cited in a numbered list essentially according to the Vancouver Uniform Requirements (5th ed., Ann Intern Med 1997;126(1):36-47).
References should contain names of all authors in small letters (surnames first followed by initials), Title of communication in lower
case lettering, Title of Journal [abbreviated according to International Serials Data System-List of Serial title Word Abbreviations,
1985 (ISDS-ISO International Centre, 20 rue Bachaumont, 75002 Paris, France)], year of publication; volume number: first and last page
number (see Ref.1).
Reference to Journal Supplement, cf. example (Ref. 2).
References to books should contain Author Name(s)
in the same format as above: Title. Publisher's location: Name; Year of publication. page range (see Ref. 3).
References to multi-author
books with editor(s) should contain Author Name(s) in the same format as above: Title of contribution. In: Name(s) of editor(s). Title
of book. Publisher's location: Name; Year of publication. If necessary page range (see Ref. 4)
For communications which have been
accepted for publication, but not yet printed, the reference must contain the journal name and year (see Ref. 5).
Material referred
to by the phrase "personal communication" or "submitted for publication" are not considered full references and should
only be placed in parentheses at the appropriate place in the text, e.g., (Hessel 1997 personal communication).
Examples of references
are shown below.
1. Ordljin TM, Shainoff JR, Lawrence SO, and Simpson-Haidaris PJ. Thrombin cleavage enhances exposure of heparin
binding domain in the N-terminus of the fibrin beta chain. Blood 1996;88:2050-61.
2. Copley AL. The endoendothelial fibrin lining.
Thromb Res 1983;(SV):1-154.
3. Davies JT, Rideal EK. Interfacial Phenomena. New York-London: Academic Press; 1961. p. 110-30.
4. Blomback B. Fibrinogen to fibrin transformation. In: Seegers WH, editor. Blood Clotting Enzymology. New York-London: Academic
Press; 1967. p. 143-215.
5. Leshner AI. Molecular mechanisms of cocaine addiction. N Engl J Med. In Press 1996. (e) Tables
and Figures: Tables and figures are submitted via the online submission system EES with the accompanying article. Each Table should
be included on a separate page. Tables should supplement but not duplicate the text. A brief title should be provided for each. Abbreviations
used in Tables should be defined. Legends to Tables should be included at the end of the manuscript file. Figures should be in black
and white, all details clear enough to permit reproduction, and legible in the actual size in which they should be published. If the
number of tables and/or figures is excessive, the author(s) could be asked to eliminate some of them. Authors requesting color figures
in the print version of the Journal will be required to share in their production expenses. Thrombosis Research is part of the
programme "Colourful e-Products". This allows illustrations that appear in black and white in the print version of the Journal
to be included in colour online, in ScienceDirect. Authors wishing to make use of this facility should ensure that the artwork is in
an acceptable format (TIFF, EPS, or MS Office files) and at the correct resolution. In addition, for colour online and black and white
in print, both colour and black and white artwork (file and/or hard copy as specified above) must be provided. There is no extra charge
for authors who participate in this facility. For more detailed specification on submitting electronic illustrations, please see the
following webpage: http://www.elsevier.com/locate/authorartwork
Copyright: Upon acceptance of an article, authors
will be asked to sign a "Journal Publishing Agreement" (for more information on this and copyright see http://www.elsevier.com/wps/find/authorshome.authors/copyright).
Acceptance of the agreement will ensure the widest possible dissemination of information. An email (or letter) will be sent to the corresponding
author confirming receipt of the manuscript together with a "Journal Publishing Agreement" form.
If excerpts from other
copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the
article. Elsevier has preprinted forms for use by authors in these cases: contact Elsevier's Rights Department, Philadelphia, PA, USA:
Tel. (+1) 215 238 7869; Fax (+1) 215 238 2239; email healthpermissions@elsevier.com. Reqiests may also be completed online
via the Elsevier homepage (http://www.elsevier.com/locate/permissions).
Peer Review: Regular Articles, Review
Articles, Short Communications and Mini-Reviews are subjected to review by two referees. Acceptance is based upon the significance, originality
and validity of the material presented. If you are interested in reviewing for the Journal, please contact the Editors-in-Chief.
Revised Manuscripts: When returning a revised manuscript to the Editor, provide a covering letter in the 'Enter Comments' section
of Editorial Manager, replying to the Editor's and referees' comments, describing the changes which have been made in the revised version.
Highlight the changes in the revised manuscript to facilitate editorial reassessment. Time for revision must never exceed 60 days.
Special Subject Repositories: Certain repositories such as PubMed Central ("PMC") are authorized under special arrangement
with Elsevier to process and post certain articles. The following agreements have been established for authors whose articles have been
accepted for publication in an Elsevier journal and whose underlying research is supported by one of the following funding bodies:
• National Institutes of Health. Elsevier will send a version of the author's accepted manuscript that includes author revisions
following peer-review for public access posting 12 months after final publication. Because the NIH 'Public Access' policy is voluntary,
authors may elect not to deposit such articles in PMC. If you wish to 'opt out' and not deposit to PMC, you may indicate this by sending
an e-mail to NIHauthorrequest@elsevier.com. More information regarding the agreement between Elsevier and the National
Institutes of Health can be found at http://www.elsevier.com/wps/find/authorshome.authors/nihauthorrequest • The
Wellcome Trust. Elsevier will send to PMC the version of the author's manuscript that reflects all author-agreed changes including
those made post peer review, for public access posting immediately after final publication. Authors are required to initially subsidize
their manuscript with fees reimbursed by the Wellcome Trust. Wellcome Trust authors, whose manuscripts are subsidized, will have the
corresponding articles made free to non-subscribers on http://www.sciencedirect.com/ and Elsevier's electronic publishing
platforms. More information regarding the agreement between Elsevier and The Wellcome Trust can be found at http://www.elsevier.com/wps/find/authorshome.authors/wellcometrustauthors
III. GALLEY PROOFS.
One set of page proofs in PDF format will be sent by e-mail to the corresponding author (if we do
not have an e-mail address then paper proofs will be sent by post). Elsevier now sends PDF proofs which can be annotated; for this you
will need to download Adobe Reader version 7 available free from http://www.adobe.com/products/acrobat/readstep2.html. Instructions
on how to annotate PDF files will accompany the proofs. The exact system requirements are given at the Adobe site: http://www.adobe.com/products/acrobat/acrrsystemreqs.html#70win
If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return
to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections
and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail,
or by post.
Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and
figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the
Editor. We will do everything possible to get your article published quickly and accurately. Therefore, it is important to ensure that
all of your corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent
corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of
your article if no response is received.
Offprints: The corresponding author, at no cost, will be provided with a PDF file
of the article via e-mail or, alternatively, 25 free paper offprints. The PDF file is a watermarked version of the published article
and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use. Additional paper
offprints can be ordered by the authors. An order form with prices will be sent to the corresponding author.
